Show simple item record

dc.contributor.authorLeeson, Simon C
dc.contributor.authorAlibegashvili, Tamar
dc.contributor.authorArbyn, Marc
dc.contributor.authorBergeron, Christine
dc.contributor.authorCarriero, Carmine
dc.contributor.authorMergui, Jean-Luc
dc.contributor.authorNieminen, Pekka
dc.contributor.authorPrendiville, Walter
dc.contributor.authorRedman, Charles W E
dc.contributor.authorRieck, Gudrun C
dc.contributor.authorQuaas, Jens
dc.contributor.authorPetry, K Ulrich
dc.date.accessioned2014-11-19T10:20:34Z
dc.date.available2014-11-19T10:20:34Z
dc.date.issued2014-01
dc.identifier.citationLeeson, S.C. et al., 2014. The future role for colposcopy in Europe. Journal of Lower Genital Tract Disease, 18 (1), pp 70-8en_GB
dc.identifier.issn1526-0976
dc.identifier.pmid23774077
dc.identifier.doi10.1097/LGT.0b013e318286b899
dc.identifier.urihttp://hdl.handle.net/10147/335795
dc.description.abstractImprovements in the performance of cervical screening may be limited by the diagnostic performance of colposcopy. Nonetheless, colposcopy remains the best available tool to assess women considered at high risk for having or developing cervical cancer. The provision and role of colposcopy across Europe is variable. Introduction of vaccination against human papillomavirus (HPV) types 16 and 18 as well as the possible switch to HPV-based screening is likely to change the profiles of women presenting to colposcopy services and provide management difficulties for the colposcopist.The standard of colposcopy in Europe can be maintained or improved despite a variable availability of screening. The prevalence of cervical intraepithelial neoplasia grade 3 may decrease for women having had HPV vaccination. The incidence of cervical intraepithelial neoplasia grade 3 and cervical cancer in second and subsequent rounds of HPV-based screening are likely to decrease compared to cytology-based screening. In HPV-based screening, the numbers of women with no detectable or minor abnormalities at colposcopy and with screen-detected glandular disease are likely to increase. We have considered how these issues will affect states that have varying implementation of organized cervical screening programs and varying degrees of implementation of HPV testing or vaccination.The development of quality assurance across Europe accompanying these program changes is discussed.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of lower genital tract diseaseen_GB
dc.subjectCERVICAL CANCERen_GB
dc.subjectSCREENINGen_GB
dc.subject.meshCervical Intraepithelial Neoplasia
dc.subject.meshColposcopy
dc.subject.meshEarly Detection of Cancer
dc.subject.meshEurope
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshUterine Cervical Neoplasms
dc.titleThe future role for colposcopy in Europe.en_GB
dc.typeArticleen
dc.contributor.department1Department of Obstetrics and Gynaecology, Betsi Cadwaladr University Health Board, Bangor, Gwynedd, UK; 2Department of Gynecology, National Screening Center, Tbilisi, Georgia; 3Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium; 4Laboratoire Cerba, Paris, France; 5Department of Gynecology and Obstetrics, University of Bari, Bari, Italy; 6Hôpital Tenon, Service de Gynécologie Obstétrique et Médecine de la Reproduction, Paris, France; 7Department of Obstetrics and Gynecology, Helsinki University Hospital, Finland; 8The Beacon Hospital, Sandyford, Dublin, Ireland; 9Department of Obstetrics and Gynaecology, University Hospital of North Staffordshire, Stoke-on-Trent, UK; 10D-18437 Stralsund, Grünthal, Germany; and 11Department of Obstetrics and Gynaecology, Klinikum Wolfsburg, Wolfsburg, Germany.en_GB
dc.identifier.journalJournal of lower genital tract diseaseen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
html.description.abstractImprovements in the performance of cervical screening may be limited by the diagnostic performance of colposcopy. Nonetheless, colposcopy remains the best available tool to assess women considered at high risk for having or developing cervical cancer. The provision and role of colposcopy across Europe is variable. Introduction of vaccination against human papillomavirus (HPV) types 16 and 18 as well as the possible switch to HPV-based screening is likely to change the profiles of women presenting to colposcopy services and provide management difficulties for the colposcopist.The standard of colposcopy in Europe can be maintained or improved despite a variable availability of screening. The prevalence of cervical intraepithelial neoplasia grade 3 may decrease for women having had HPV vaccination. The incidence of cervical intraepithelial neoplasia grade 3 and cervical cancer in second and subsequent rounds of HPV-based screening are likely to decrease compared to cytology-based screening. In HPV-based screening, the numbers of women with no detectable or minor abnormalities at colposcopy and with screen-detected glandular disease are likely to increase. We have considered how these issues will affect states that have varying implementation of organized cervical screening programs and varying degrees of implementation of HPV testing or vaccination.The development of quality assurance across Europe accompanying these program changes is discussed.


This item appears in the following Collection(s)

Show simple item record